A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced
or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been
determined (phase I trial).
Assessement of the efficacy and safety of a low-dose of regorafenib (80mg/day) with avelumab
in patients with advanced or metastatic colorectal tumors.